FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220740895> ?p ?o ?g. }

• W4220740895 endingPage "563" @default.
• W4220740895 startingPage "553" @default.
• W4220740895 abstract "The programmed death-1 (PD-1) inhibitor nivolumab prolongs disease-free survival in patients with muscle-invasive urothelial carcinoma (MIUC). To evaluate the effects of nivolumab on health-related quality of life (HRQoL) after radical resection in patients with MIUC. We used data from 709 patients in CheckMate 274 (NCT02632409; 282 with programmed death ligand 1 [PD-L1] expression ≥1%), an ongoing randomized, double-blind, placebo-controlled phase 3 trial of adjuvant nivolumab. Intravenous injection of nivolumab (240 mg) or placebo every 2 wk for ≤1 yr. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EQ-5D-3L. Linear mixed-effect models for repeated measures were used to compare nivolumab and placebo on changes in HRQoL. Time to confirmed deterioration (TTCD) of HRQoL was analyzed by Cox proportional hazards regression. In the full HRQoL evaluable population, no clinically meaningful deterioration of HRQoL was observed in either treatment arm. Moreover, nivolumab was noninferior to placebo on changes from baseline for all main outcomes. The median TTCD for fatigue was 41.0 wk for nivolumab and 44.3 wk for placebo (hazard ratio [HR]: 1.11, 95% confidence interval [CI], 0.89–1.39). For the visual analog scale, the median TTCD was not reached for nivolumab and it was 57.6 wk for placebo (HR: 0.78, 95% CI, 0.61–1.00). The median TTCD for the other main outcomes was not reached in either treatment arm. The findings were similar for patients with PD-L1 expression ≥1%. These results demonstrate that nivolumab did not compromise the HRQoL of patients with MIUC in CheckMate 274. Nivolumab is being researched as a new treatment for patients with bladder cancer (urothelial carcinoma). We found that nivolumab maintained quality of life while increasing the time until cancer returns in patients whose bladder cancer had spread or grown and who had unsuccessfully tried platinum-containing chemotherapy." @default.
• W4220740895 created "2022-04-03" @default.
• W4220740895 creator A5000689501 @default.
• W4220740895 creator A5011644019 @default.
• W4220740895 creator A5018275141 @default.
• W4220740895 creator A5030962499 @default.
• W4220740895 creator A5041974040 @default.
• W4220740895 creator A5052290056 @default.
• W4220740895 creator A5059990105 @default.
• W4220740895 creator A5064884168 @default.
• W4220740895 creator A5065597096 @default.
• W4220740895 creator A5067456208 @default.
• W4220740895 creator A5079215307 @default.
• W4220740895 creator A5080168319 @default.
• W4220740895 date "2022-10-01" @default.
• W4220740895 modified "2023-09-26" @default.
• W4220740895 title "Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial" @default.
• W4220740895 cites W1506319576 @default.
• W4220740895 cites W1524063860 @default.
• W4220740895 cites W1947168884 @default.
• W4220740895 cites W1970354784 @default.
• W4220740895 cites W1971903914 @default.
• W4220740895 cites W2022924076 @default.
• W4220740895 cites W2084075250 @default.
• W4220740895 cites W2098428600 @default.
• W4220740895 cites W2103607521 @default.
• W4220740895 cites W2128238301 @default.
• W4220740895 cites W2132219433 @default.
• W4220740895 cites W2137616140 @default.
• W4220740895 cites W2138662111 @default.
• W4220740895 cites W2163963638 @default.
• W4220740895 cites W2473786944 @default.
• W4220740895 cites W2582671354 @default.
• W4220740895 cites W2752227448 @default.
• W4220740895 cites W2789128713 @default.
• W4220740895 cites W2803287610 @default.
• W4220740895 cites W2886675419 @default.
• W4220740895 cites W2900373509 @default.
• W4220740895 cites W2906639914 @default.
• W4220740895 cites W2912440854 @default.
• W4220740895 cites W2921535378 @default.
• W4220740895 cites W2940821318 @default.
• W4220740895 cites W2946620483 @default.
• W4220740895 cites W2959688418 @default.
• W4220740895 cites W2990281693 @default.
• W4220740895 cites W3003402209 @default.
• W4220740895 cites W3007264925 @default.
• W4220740895 cites W3018173829 @default.
• W4220740895 cites W3020989907 @default.
• W4220740895 cites W3023288864 @default.
• W4220740895 cites W3092138236 @default.
• W4220740895 cites W3126200693 @default.
• W4220740895 cites W3148827278 @default.
• W4220740895 cites W3163995648 @default.
• W4220740895 cites W4205125979 @default.
• W4220740895 cites W4293241248 @default.
• W4220740895 doi "https://doi.org/10.1016/j.euo.2022.02.003" @default.
• W4220740895 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35288066" @default.
• W4220740895 hasPublicationYear "2022" @default.
• W4220740895 type Work @default.
• W4220740895 citedByCount "3" @default.
• W4220740895 countsByYear W42207408952022 @default.
• W4220740895 countsByYear W42207408952023 @default.
• W4220740895 crossrefType "journal-article" @default.
• W4220740895 hasAuthorship W4220740895A5000689501 @default.
• W4220740895 hasAuthorship W4220740895A5011644019 @default.
• W4220740895 hasAuthorship W4220740895A5018275141 @default.
• W4220740895 hasAuthorship W4220740895A5030962499 @default.
• W4220740895 hasAuthorship W4220740895A5041974040 @default.
• W4220740895 hasAuthorship W4220740895A5052290056 @default.
• W4220740895 hasAuthorship W4220740895A5059990105 @default.
• W4220740895 hasAuthorship W4220740895A5064884168 @default.
• W4220740895 hasAuthorship W4220740895A5065597096 @default.
• W4220740895 hasAuthorship W4220740895A5067456208 @default.
• W4220740895 hasAuthorship W4220740895A5079215307 @default.
• W4220740895 hasAuthorship W4220740895A5080168319 @default.
• W4220740895 hasBestOaLocation W42207408951 @default.
• W4220740895 hasConcept C121608353 @default.
• W4220740895 hasConcept C126322002 @default.
• W4220740895 hasConcept C126894567 @default.
• W4220740895 hasConcept C141071460 @default.
• W4220740895 hasConcept C142724271 @default.
• W4220740895 hasConcept C143998085 @default.
• W4220740895 hasConcept C159110408 @default.
• W4220740895 hasConcept C168563851 @default.
• W4220740895 hasConcept C204787440 @default.
• W4220740895 hasConcept C207103383 @default.
• W4220740895 hasConcept C27081682 @default.
• W4220740895 hasConcept C2777701055 @default.
• W4220740895 hasConcept C2779951463 @default.
• W4220740895 hasConcept C2780030458 @default.
• W4220740895 hasConcept C2908647359 @default.
• W4220740895 hasConcept C44249647 @default.
• W4220740895 hasConcept C50382708 @default.
• W4220740895 hasConcept C71924100 @default.
• W4220740895 hasConcept C99454951 @default.
• W4220740895 hasConceptScore W4220740895C121608353 @default.
• W4220740895 hasConceptScore W4220740895C126322002 @default.

• next